These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25534993)

  • 1. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    Shiota M; Yokomizo A
    Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
    [No Abstract]   [Full Text] [Related]  

  • 4. Is in vitro-acquired resistance to enzalutamide a useful model?
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
    Thomson D; Charnley N; Parikh O
    Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistance.
    Fenner A
    Nat Rev Urol; 2014 Aug; 11(8):424. PubMed ID: 24980198
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
    Lorente D; Bianchini D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; De Bono JS
    Eur J Cancer; 2014 Mar; 50(5):1042-3. PubMed ID: 24433842
    [No Abstract]   [Full Text] [Related]  

  • 9. Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients.
    Mellado B; Jimenez N; Marin-Aguilera M; Reig O
    Clin Genitourin Cancer; 2016 Aug; 14(4):265-70. PubMed ID: 26827258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Roles of enzalutamide in castrate-resistant prostate cancer].
    Kamba T
    Nihon Rinsho; 2016 May; 74 Suppl 3():632-9. PubMed ID: 27344807
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
    van Soest RJ; de Wit R; van Weerden WM
    Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic alterations drive enzalutamide resistance.
    Masone MC
    Nat Rev Urol; 2023 Aug; 20(8):456. PubMed ID: 37430169
    [No Abstract]   [Full Text] [Related]  

  • 13. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
    Francini E; Roviello G
    Tumour Biol; 2014 Aug; 35(8):7391-2. PubMed ID: 24874054
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer: Fitting to overcome enzalutamide resistance.
    Thoma C
    Nat Rev Urol; 2016 Oct; 13(10):564-5. PubMed ID: 27549359
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous targeting of the Akt and androgen receptor pathways.
    Wirth MP; Froehner M
    Eur Urol; 2015 Jun; 67(6):991-992. PubMed ID: 25199717
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer: Sequencing AR-targeted agents might be ineffective in mCRPC.
    Heidenreich A; Pfister D
    Nat Rev Urol; 2015 May; 12(5):246-7. PubMed ID: 25868561
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate Cancer: Box clever--YB-1 has a role in CRPC.
    Stone L
    Nat Rev Urol; 2016 Apr; 13(4):183. PubMed ID: 26902340
    [No Abstract]   [Full Text] [Related]  

  • 18. Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Culig Z
    Eur Urol; 2018 Jan; 73(1):9-10. PubMed ID: 28890248
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer: PREVAILing wind blows more good news for enzalutamide.
    Fenner A
    Nat Rev Urol; 2015 Jun; 12(6):304. PubMed ID: 25917887
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men with Castration-Resistant Prostate Cancer: Results from the Randomised, Phase 3 AFFIRM Trial.
    Taneja SS
    J Urol; 2015 Aug; 194(2):392-3. PubMed ID: 26195363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.